Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | UBE2M | P61081 | 1/20 | 0.55 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 9/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315248 | 0.87 | MGLL (0.57) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL315755 | 0.86 | MEN1 (0.61) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL5802062 | 0.80 | MGLL (0.54) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL315088 | 0.79 | TSHR (0.72) | MEN1KMT2AMGLLHSD11B1 | |
| SCHEMBL315815 | 0.77 | MGLL (0.67) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL314394 | 0.76 | ALDH1A1 (0.41) | MEN1KMT2A | |
| SCHEMBL25172112 | 0.75 | ALDH1A1 (0.58) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL23410959 | 0.74 | KMT2A (0.67) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL29967110 | 0.74 | KMT2A (0.67) | MEN1KMT2AUBE2MDCUN1D1MGLL | |
| SCHEMBL8285698 | 0.74 | MGLL (0.62) | MEN1KMT2AUBE2MDCUN1D1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | MEN1 2639/4885KMT2A 3968/4885UBE2M 4163/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MEN1 1081/4885KMT2A 1134/4885UBE2M 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.